- Home
- LYEL vs WIW Comparison
LYEL vs WIW Comparison
Compare LYEL & WIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LYEL | WIW |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 548.9M | 529.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LYEL | WIW |
|---|---|---|
| Price | $23.00 | $8.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 89.8K | ★ 242.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.14% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $8.33 |
| 52 Week High | $45.00 | $9.03 |
Technical Indicators
Market Signals| Indicator | LYEL | WIW |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 45.58 |
| Support Level | $21.72 | $8.47 |
| Resistance Level | $27.30 | $8.63 |
| Average True Range (ATR) | 2.60 | 0.05 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 36.63 | 26.67 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income. Capital appreciation, when consistent with current income, is a secondary investment objective. The fund operates as a single operating segment, which is an investment portfolio.